Market Analysis and Insights: Global Neuropathic Pain Drugs Market
Neuropathic pain is pain caused by damage or disease affecting the somatosensory nervous system. Neuropathic pain may be associated with abnormal sensations called dysesthesia or pain from normally non-painful stimuli (allodynia).
The global Neuropathic Pain Drugs market size is projected to reach US$ million by 2030, from US$ million in 2022, at a CAGR of % during 2023-2030.
In terms of value, North America is a large market and is expected to increase at over 5% CAGR during the forecast period. The Asia Pacific neuropathic pain management market is projected to show fast growth and it is projected grow at CAGR of 6% over the forecast period due to increasing prevalence of diabetes in Asia Pacific, particularly in China and India.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neuropathic Pain Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neuropathic Pain Drugs market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neuropathic Pain Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neuropathic Pain Drugs market.
Global Neuropathic Pain Drugs Scope and Market Size
Neuropathic Pain Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Neuropathic Pain Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2030.
Segment by Type
Tricyclic Anti-Depressants Anticonvulsants
Serotonin-Norepinephrine Reuptake Inhibitor
Capsaicin Cream
Local Anaesthesia
Opioids
Steroids
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Pfizer
Johnson & Johnson
Sanofi
GlaxoSmithKline
Eli Lilly
Bristol-Myers Squibb
Biogen
Baxter Healthcare
Depomed
